YYYanjuan Yu

Yanjuan Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yanjuan Yu has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Chaohui Chen

    Respiratory Department Children's Hospital Affiliated to Zhengzhou University, Henan Children's hospital, Zhengzhou Children's Hospital Zhengzhou China

    1 shared publication
  • Chunbo Hao

    Henan International Joint Laboratory of Children's Infectious Diseases, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, China

    1 shared publication
  • Fang Wang

    Department of Infectious Diseases, Henan Children’s Hospital, Children’s Hospital Affiliated to Zhengzhou University, Zhengzhou Children’s Hospital, Zhengzhou, China

    1 shared publication
  • Gaijing Jia

    Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China

    1 shared publication
  • Genhao Wang

    Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China

    1 shared publication
  • Guangcai Duan

    Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, China

    1 shared publication

Latest Publications

  • Efficacy of High‐Dose Versus Conventional‐Dose Methylprednisolone in Reducing the Risk of Chronic Lung Disease in Chinese Children With Severe Mycoplasma pneumoniae Pneumonia: A Retrospective Study

    by Yanyan Su, Yanjuan Yu, Lei Zhang, Yu Tang, Min Li, Chaohui Chen, Shasha Xu, Yanqiong Wang, Yuemei Liu, Haiming Yang, et al.

    Background: This study aimed to compare the clinical efficacy of high‐dose versus conventional‐dose methylprednisolone therapy and the prevalence of chronic lung disease (CLD) at the 6‐month follow‐up in Chinese children with severe Mycoplasma pneumoniae pneumonia (SMPP). Methods: A retrospective cohort study was performed on 82 children with SMPP admitted from January 2018 to January 2024. Patients were categorized into high‐dose and conventional‐dose groups based on initial glucocorticoid dosage. Clinical data, laboratory tests, chest imaging, and bronchoscopy findings were reviewed to compare pulmonary conditions and therapeutic efficacy. The prevalence of CLD, oxygen saturation levels, and pulmonary function were assessed at the 6‐month follow‐up. Results: The main clinical features of SMPP included persistent high fever, cough, excessive inflammation (C‐reactive protein, erythrocyte sedimentation rate, procalcitonin, interleukin‐6, lactate dehydrogenase, serum ferritin, and D‐Dimer), as well as severe pulmonary involvement, including consolidation, pleural effusion, and lung necrosis on computed tomography, and mucus plugging on bronchoscopy. Disease severity was comparable between groups, but the high‐dose group exhibited a shorter fever duration (9.8 vs. 16.1 days), faster defervescence after corticosteroid treatment (1.0 vs. 7.0 days), and reduced hospitalization (13.4 vs. 18.4 days) (all p < 0.001). At the 6‐month follow‐up, the high‐dose group had a significantly lower prevalence of CLD (28.2% vs. 85.4%) ( p < 0.001), higher oxygen saturation levels ( p = 0.033) and better pulmonary function ( p < 0.001). Conclusion: High‐dose methylprednisolone therapy was more effective than conventional‐dose treatment for SMPP patients. It was also associated with a lower prevalence of CLD, higher oxygen saturation levels, and better pulmonary function outcomes.

  • Open Access

    High-Risk CCL14 lineage drives severe Mycoplasma pneumoniae pneumonia in children: a study in central China

    by Chunbo Hao, Zijie Li, Yanjuan Yu, Song Wang, Genhao Wang, Gaijing Jia, Tiantian Sun, Shouhang Chen, Yang Wu, Yu Tang, et al.

    Background: The post–coronavirus disease 2019 (COVID-19) pandemic resurgence of Mycoplasma pneumoniae (MP) infections, particularly in China, underscores the need to understand the drivers of disease severity.Purpose: This study aimed to evaluate the association between predominantly circulating MP strains and disease severity in Henan Province, central China.Methods: We integrated the clinical data of 3,060 pediatric patients and analyzed the epidemiological characteristics of MP pneumonia (MPP) in the Henan region in 2020–2024. Bronchoalveolar lavage fluid collected from 137 patients was analyzed using multilocus sequence typing and multilocus variable number tandem-repeat analysis to investigate the correlation between genotype and clinical outcome.Results: A significant post-COVID MPP outbreak was predicted in 2023. Genotyping revealed the cocirculation of 2 major genotypes: the prevalent ST3 (57.7%, severe ratio [31.6%]) and the less common but highly virulent ST14 (26.3%, severe ratio [72.2%]). Phylogenetic clustering confirmed ST14/3-5-6-2 as part of a broader hypervirulent lineage, common cluster label 14 (CCL14), which was significantly associated with disease severity (χ2=19.39; P<0.001). Patients infected with CCL14 strains exhibited a distinct hyperinflammatory profile marked by elevated D-dimer levels, complement C4 levels, and platelet count. The mutation ratio of macrolide resistance sites in the MP strains from Henan Province was approximately 75%.Conclusion: Our findings identified the CCL14 lineage as a key driver of disease severity in macrolide-resistant pediatric MPP in Henan Province, China. This under scores the importance of integrating molecular surveillance with clinical monitoring to mitigate disease burden.